drugset
drugset / Trial / NCT07441369

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

NCT07441369 ↗

Phase 2 Enrolling by invitation 16 enrolled Fudan University Shanghai Cancer Hospital, China · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, single-arm, open-label clinical study, to explore the efficacy and safety of abemaciclib combined with FOLFOX/FOLFIRI regimen in patients with advanced colorectal liver metastases cancer who failed standard two or three-line therapy.

Timeline

Start
2026-05-01
Primary completion
2027-04-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 100 mg Oral
Subject Abemaciclib Small molecule 200 mg Oral
Background Irinotecan Small molecule 180 mg/m2 Intravenous
Background Leucovorin Small molecule 200 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

metastasis from malignant tumor of colon